Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
- Registration Number
- NCT00352560
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The main purpose of the study is to compare the mean AERP between treatment groups based on the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- Recurrent PAF with indication for catheter ablation
Exclusion Criteria
- Struct. Cardiopathy
- Mitral valve disease
- VEF<40%
- Myocardiopathy
- LVH
- cardiac surgery
- AF reversible
- QT c>450
- Recent MI/stroke, severe HTN
- Requirement of ACEI/ARBs
- Coronary synd., HTA, liver disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description B Placebo - A Irbesartan -
- Primary Outcome Measures
Name Time Method Irbesartan effect on duration of Atrial Effective Refractory Period (AERP) in paroxysmal AF (PAF) patients. The measures are taken after 31 days of irbesartan treatment
- Secondary Outcome Measures
Name Time Method Irbesartan effect on A Function RP The measures are taken after 31 days of irbesartan treatment Irbesartan effect on atrial conduction intervals after basal & extra-stimuli, in PAF patients The measures are taken after 31 days of irbesartan treatment Refractoriness dispersion The measures are taken after 31 days of irbesartan treatment
Trial Locations
- Locations (1)
Local Institution
🇪🇸Madrid, Spain